ICIs
1 clinical trial
1 product
85 abstracts
1 indication
Abstract
A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).Org: Columbia University Irving Medical Center, New York, NY, USA, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Montefiore Einstein Comprehensive Cancer Center, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Health,
Abstract
LOOP: An observational, prospective, multicenter study of patients with non-small cell lung cancer in the US receiving standard-of-care and initiating an approved therapy with risk of pneumonitis/ILD.Org: Waltham, MA,
Abstract
Association between circulating cytokines expression patterns and outcomes to immune-checkpoint (ICI)–based regimens in metastatic renal cell carcinoma (mRCC).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Arthralgia in patients with cancer receiving immune checkpoint inhibitor: A systematic review and meta-analysis.Org: University of Hawaii Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, John A. Burns School of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel,
Abstract
Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Hematology/Oncology Fellowship, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC).Org: School of Medicine, Kyungpook National University, Daegu, South Korea, Picture Health, Cleveland, OH, Kyungpook National University Hospital, Daegu, South Korea, University of Texas at Austin, Weatherford, TX, Picture Health Inc., Cleveland, OH, Feinberg School of Medicine, Chicago, IL, Feinberg School of Medicine, Northwestern University, Chicago, IL, Richmond University Medical Center, Staten Island, NY, Northwestern University, Chicago, IL, University Hospitals Cleveland Medical Center, Cleveland, OH, Perlmutter Cancer Center, NYU Langone Health, New York, NY,
Abstract
A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.Org: UofL Health – Brown Cancer Center,
Abstract
Synergistic antitumor activity of METTL3 peptide degrader and immune checkpoint inhibitor in advanced urothelial cancer.Org: School of Biomedical Sciences, Hunan University, First Affiliated Hospital of Air Force Military Medical University,
Abstract
Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.Org: Washington University in St. Louis, Medical College of Georgia at Augusta University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia.Org: Japanese Red Cross Medical Center, Tokyo, Japan, Sendai Kousei Hospital, Sendai, Japan, Yamaguchi-Ube Medical Center, Yamaguchi, Japan, Chiba Cancer Center, Chiba, Japan, Kobe City Medical Center General Hospital, Kobe, Japan,
Abstract
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.Org: Far Eastern Memorial Hospital, Salem,
Abstract
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.Org: Affiliated Cancer Hospital of Chongqing University,
Abstract
Therapeutic potential of immune-cold solid tumors through homologous recombination deficiency.Org: OneCell Dx Inc., OneCell Dx, Indx Technology, OneCell Diagnostics,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade.Org: Campus Biomedico, Santa Maria della Misericordia Hospital,
Abstract
The prevalence of RCTs in PARP and immune-checkpoint blockade combination trials: An appraisal of clinical evidence generation in oncology.Org: Beth Israel Deaconess Medical Center, Boston, MA, Cancer Research Institute, New York City, NY, New York, NY,
Abstract
Real-world survival outcomes associated with immunotherapy followed with anti-vascular targeted therapy for metastatic clear cell renal cell carcinoma.Org: Jinan, Shandong, China,
Clinical trial
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world StudyStatus: Completed, Estimated PCD: 2023-06-30
Abstract
Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).Org: Department of Medical, Surgical and Health Sciences, University of Trieste, Medical Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Foch Hospital, Centre Hospitalier Universitaire de Grenoble (France),
Abstract
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.Org: Miami Cancer Institute, Poznan University of Medical Sciences, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, General University Hospital in Prague,
Abstract
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022.Org: David Geffen School of Medicine at the University of California,
Abstract
Assessment of YouTube as an information source for immune checkpoint inhibitors (ICIs).Org: Government Medical College and Hospital, Chandigarh, India, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, University of Vermont Medical Center; Division of Hematology-Oncology, Burlington, VT, New York Presbyterian Queens, Flushing, NY, All India Institute of Medical Sciences (AIIMS), New Delhi, India,
Abstract
Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Avera Cancer Institute, Sioux Falls, SD, The University of Arizona, Tucson, AZ, Huntsman Cancer Institute,
Abstract
Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors.Org: Institut Gustave Roussy, Gustave Roussy Cancer Center, Gustave Roussy Département d'Organisation du Parcours Patient, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Paris Saclay University,
Abstract
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.Org: Nantes University Hospital, Institut de Cancérologie de l'Ouest, Angers, France, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,
Abstract
Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.Org: Xilis, Durham Veteran Affairs Medical Center, NC Medical Research, Xilis Inc, Xilis, Inc.,
Abstract
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).Org: Center for Innovations in Quality Effectiveness and Safety, Houston, TX, VA Boston Healthcare System, Boston, MA, Baylor College of Medicine,
Abstract
Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).Org: Massachusetts General Hospital, Division of Oncology, Rambam health care, Haifa, Israel, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations.Org: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Washington University School of Medicine in St Louis, Washington University in St. Louis,
Abstract
Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine,
Abstract
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.Org: Lifespan Health System, Providence, RI, Ohio State University Comprehensive Cancer Center, Columbus, OH, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Acute hospitalizations after proton beam therapy (PBT) versus intensity-modulated radiotherapy (IMRT) for locally advanced non–small-cell lung cancer (LA-NSCLC) in the era of immune checkpoint inhibitor (ICI) consolidation: A retrospective propensity score weighted study.Org: University of Pennsylvania, University of Pennsylvania Health System, New York Proton Center,
Abstract
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.Org: H. Lee Moffitt Cancer Center and Research Institute, Ohio State University Comprehensive Cancer Center, University of Virginia, Charlottesville, VA, USA, University of Colorado Denver Anschutz Medical Center, University of Southern California - Health Sciences Campus,
Abstract
Impact of WNT/B-catenin alterations and metastasis location among patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) combinations.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Corporacion Sanitaria Parc Tauli, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.Org: Foundation Medicine, Inc., Cambridge, MA, Mayo Clinic, Foundation Medicine Inc, Morrisville, NC,
Abstract
Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.Org: New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, University of Texas MD Anderson Cancer Center, NYU Grossman School of Medicine, Department of Population Health,
Abstract
Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?Org: Houston Methodist Cancer Center, Houston Methodist Hospital, Department of Pathology and Genomic Medicine,
Abstract
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.Org: Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.Org: Picture Health, University Hospitals Cleveland Medical Center, New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center, Emory University, Atlanta, GA, USA,
Abstract
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis.Org: University of Kentucky, Lexington, KY,
Abstract
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, University of Texas MD Anderson Cancer Center,
Abstract
Subsets of interferon signaling and response to immune checkpoint blockade.Org: Yale School of Medicine, University of Southern California Marshall School of Business, Yale University School of Public Health,
Abstract
Correlation of DNA methylation signatures with response to immune checkpoint inhibitors in metastatic melanoma.Org: Department of Dermatology, Medical University of Vienna, Vienna, Austria, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria, Department of Radiology, Wiener Gesundheitsverbund, Klinik Donaustadt, Medical University of Vienna,
Abstract
Sociodemographic factors affecting survival in stage IIIA NSCLC treated with surgery-based treatment or definitive chemoradiation with immunotherapy consolidation: An NCDB analysis.Org: University of Kentucky HealthCare, Markey Cancer Center, University of Kentucky, University of Kentucky, Lexington, KY, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Johnston Memorial Hospital,
Abstract
A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer.Org: Chinese People's Liberation Army General Hospital, Beijing, China, The People's Liberation Army Medical College, Beijing, China, Nankai University School of Medicine, Tianjin, China, Department of Medical Oncology, Xi'an Jiaotong UniversityDepartment of Medical Oncology, Xi'an Jiaotong University, Xi'an, China, Department of Medical Oncology, Fifth Medical Center, General Hospital of the Chinese People's Liberation Army, Beijing, China,
Abstract
Comparative assessment of manual chart review and patient-level adverse drug event identification using artificial intelligence in evaluating immunotherapy‑related adverse events (irAEs).Org: The Ohio State University - James Cancer Hospital, Department of Biomedical Informatics, The Ohio State University, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.Org: SAIHST, Sungkyunkwan University of Medicine, Samsung Medical Center,
Abstract
Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).Org: Northwestern University Feinberg School of Medicine, Northwestern Medicine Devleopmental Therapeutics Institute, Northwestern Memorial Hospital, Chicago, IL, AMITA Health Saint Francis Hospital Evanston, Kyungpook National University Hospital,
Abstract
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, The Ohio State University - James Cancer Hospital, Ohio State University College of Medicine, The Ohio State University Medical Center,
Abstract
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.Org: BostonGene, Corp., Waltham, MA, BostonGene Corporation, University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.Org: Skin Cancer Center, University Hospital Leipzig, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, Personalis, Inc.,
Abstract
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.Org: OncoHost LTD, Heidelberg University Hospital, Heidelberg, Germany, Roswell Park Cancer Institute, Sheba Medical Center, Or-Yeuda, Rambam Health Care,
Abstract
Single cell RNA sequencing to reveal immune microenvironment in primary and brain metastatic lesion of non-small cell lung cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong University Cancer Center,
Abstract
Dynamic monitoring of ctDNA to predict response to immunotherapy plus chemotherapy in BTC.Org: Eastern Hepatobiliary Surgery Hospital, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development at Jiangsu Simcere Diagnostics Co. Ltd, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji University School of Medicine,
Abstract
Effects of treatment and patterns of metastases in upper tract and bladder urothelial cancer and non-urothelial cancer based on the National Cancer Database (NCDB) analysis.Org: Inova Schar Cancer Institute, Georgetown University Medical School,
Abstract
Quantitative analysis of MMR deficiency in dMMR/MSI high CRC and levels of instability: Implications for ICI therapy of dMMR tumors.Org: Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Clinical Hospital “Acibadem Sistina”, University Clinic for Radiotherapy and Oncology, University Clinic for Abdominal Surgury, Center for Genetic Engineering and Biotechnology "Georgi D. Efremov",
Abstract
Time to treatment initiation in a retrospective cohort of patients with advanced lung cancer treated with an immune checkpoint inhibitor.Org: Wake Forest Baptist Medical Center, Winston-Salem, NC,
Abstract
Efficacy and safety of radiation therapy combined with anti-angiogenic agents and immunotherapy for MSS/pMMR metastatic colorectal cancer: A real-world study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Department of Abdominal Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliate Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.Org: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan,
Abstract
Atypical response patterns in Chinese patients with cancer with immune checkpoint blockade.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital with Shandong First Medical University, Jinan, China,
Abstract
Patterns and outcomes of palliative radiation therapy with immunotherapy in locally recurrent head and neck squamous cell carcinoma.Org: Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A retrospective analysis.Org: University of Connecticut School of Medicine, University of Connecticut Health Center,
Abstract
The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments.Org: University of Bologna, Medical Oncology Group, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”,
Abstract
Association of immune checkpoint inhibitors (ICI) and venous thromboembolism (VTE) in non–small-cell lung cancer (NSCLC): A single healthcare system experience.Org: Baton Rouge General Medical Center - Bluebonnet, Louisiana State University Health Sciences Center Shreveport,
Abstract
A single-centre experience of immune checkpoint inhibitors in patients with cancer in the Top End of the Northern Territory, Australia from 2016 to 2021.Org: Royal Darwin Hospital,
Abstract
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.Org: Division of Oncology/Hematology, Kantonsspital Graubuenden, Chur, Switzerland, Divison of Oncology/Hematology, Hirslanden Zurich, Zurich, Switzerland, Competence Center Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland, Internal Medicine II, Landeskrankenhaus Feldkirch, Feldkirch, Austria, Swiss Tumor Institute, Zurich, Switzerland,
Abstract
Association between body mass index and survival outcomes for patients with advanced non–small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Jinan Central Hospital affiliated to Shandong First Medical University,
Abstract
The efficacy and safety of donafenib-containing regimens as postoperative adjuvant therapy for hepatocellular carcinoma (HCC): A multicenter retrospective study.Org: Hepatobiliary Center of The First Affiliated Hospital Nanjing Medical University, Nanjing, Jiangsu, Nanjing, China, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Abstract
Immunotherapy combined with rh-endostatin improved clinical outcomes over ICIs plus chemotherapy for second-line treatment of advanced NSCLC.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China.,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.Org: Department of Respiratory Diseases, ELK Berlin, Universitätsklinikum Gießen und Marburg, Medizinische Klinik IV, Organonkologie, Innere Medizin V, Medizinische Klinik, Universitätskliniken des Saarlandes, Department of Internal Medicine, Klinikum Chemnitz GmbH,
Abstract
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma (AM) in patients with concomitant chronic lymphocytic leukemia (CLL).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Alexandra Hospital and University of Queensland, Mayo Clinic,
Abstract
Association of cannabis use with real-world time to treatment discontinuation (rwTTD) in patients with advanced cancer initiating immune checkpoint inhibition (ICI).Org: HealthPartners Institute, Memorial Sloan Kettering Cancer Center, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Forian Inc.,
Abstract
Circulating exosomal PD-L1 to predict response with immunotherapy in patients with advanced cervical cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences,
Abstract
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).Org: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tohoku University Graduate School of Medicine, Nippon Medical School Hospital, Niigata University Graduate School of Medical and Dental Sciences, Japanese Red Cross Okayama Hospital,
Abstract
Comparing survival and clinical characteristics of patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy less than and more than 2 years.Org: University of Miami Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL, Sylvester Comprehensive Cancer Center, Miami, FL,
Product
ICIs aloneAbstract
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The Immunowave study.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Wave Health,
Abstract
Prediction of brain metastases progression and overall survival in patients with metastatic non-small cell lung cancer treated by immune checkpoint inhibitors using a radiomic model.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Maastricht University Medical Centre, Grow School for Oncology and Reproduction, Hospital Clinic - IDIBAPS,
Abstract
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients.Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, University Hospital 12 de Octubre, University of Cagliari, University Hospital St Raphael, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Immune checkpoint inhibitors (ICIs) with or without anti-angiogenic agents (AAAs) and cardiovascular toxicity: A meta-analysis.Org: University of Palermo, Santa Chiara Hospital, Trento, Italy, University of Trento, CISMed, CIBIO,